New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 9, 2012
12:37 EDTVRX, MRXMedicis retreats after disclosing lawsuit against merger
Medicis (MRX) is falling after the company disclosed in an SEC filing that it had been sued by dermatological product maker Q-Med. The lawsuit alleges that Q-Med has the right to block Medicis' pending merger with Valenant Pharmaceuticals (VRX). Q-Med, whose dermal filler products are sold by Medicis, is asking a court to affirm that it has the right to block the merger, as well as a preliminary injunction that would prohibit Medicis from transferring to Valeant its right to distribute Q-Med products. Valeant agreed to buy Medicis for $44 per share in September. In early afternoon trading, Medicis fell $2.72, or 6.27%, to $40.39.
News For MRX;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 1, 2015
17:19 EDTVRXCNO Financial to replace Salix Pharmaceuticals in S&P 400 as of 4/6 close
Subscribe for More Information
06:07 EDTVRXValeant completes tender offer for Salix
Subscribe for More Information
06:05 EDTVRXValeant Pharmaceuticals International completes tender offer for Salix
Subscribe for More Information
March 30, 2015
09:02 EDTVRXMylan slips amid Abbott share sale, Teva deal for Auspex
Subscribe for More Information
March 27, 2015
07:25 EDTVRXTeva appears to be weighing transformative deal, says Bernstein
After attending Teva's (TEVA) meeting with investors, Bernstein thinks that the company is considering making a 'transformative' acquisition, although it believes that such a deal may not be imminent. The firm sees Mylan ((MYL) and the generic units of Actavis (ACT), Pfizer (PFE), and possibly Valeant (VRX) as the four logical candidates. It says that Teva can pay $81 per share for Mylan, and that a takeover of Mylan would raise Teva's EPS to about $6.50 in 2017 and $7 in 2018. Bernstein raised its price target on Teva to $69 from $60 and keeps an Outperform rating on the shares.
March 26, 2015
10:45 EDTVRXSynergy discussing possible sale with advisers, Bloomberg reports
Subscribe for More Information
March 25, 2015
12:58 EDTVRXPershing Square raises stake in Valeant, says will discuss acquisitions
Subscribe for More Information
11:59 EDTVRXPershing Square reports 5.7% stake in Valeant, will continue talks
Pershing Square expects to conduct discussions with Valeant and other relevant parties regarding strategic acquisitions by or joint ventures with the company, or other similar arrangements. These discussions would be exploratory in nature and there is no assurance that they would lead to a definitive transaction.
March 24, 2015
13:24 EDTVRXContact lens manufacturers accused of price-fixing, Bloomberg says
Subscribe for More Information
March 23, 2015
07:51 EDTVRXValeant price target raised to $240 from $185 at Susquehanna
Susquehanna raised its price target on Valeant to $240 from $185 to reflect the addition of durable assets and the improved growth trajectory its recent deals brings to its U.S. business. Susquehanna reiterated its Positive rating on Valeant shares.
07:17 EDTVRXAmerican Academy of Dermatology to hold annual meeting
73rd Annual Meeting of AAD is being held in San Francisco on March 20-24.
March 20, 2015
16:33 EDTVRXStocks end week higher after market reads Fed statement as dovish
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use